This book comprehensively explores the latest advancements in the understanding, diagnosis, and treatment of neurodegenerative diseases. The chapters provide an in-depth review of current approaches and treatment strategies for Alzheimer's disease, offering insights into the latest developments and breakthroughs. It also reviews the cutting-edge research on potential novel targets for Alzheimer's pharmacotherapy, with a focus on JNK3, GSK3, and Fyn kinase inhibitors, providing an update on related approaches and their implications. It discusses the potential of ethnomedicines as a promising tool for mitigating Alzheimer's disease, offering insights into traditional remedies and their modern applications. Additional chapters explore the influence of microglia, the neuropharmacological mechanisms associated with SARS-CoV-2, and the molecular intricacies of Parkinsons disease. The book further covers the evolving role of artificial intelligence and machine learning in the management of neurodegenerative disorders. The chapters also examine the role of nanotechnology in addressing the challenges of diseases like multiple sclerosis. Towards the end, the book examines the role of oxidative damage in neurodegeneration and its management in related disorders. This book is an important source for neuroscientists, neurologists, and students of neuroscience.
1. Comprehensive review on Alzheimers disease: Recent approaches and
treatment strategies2. Potential Novel Molecular Targets at the forefront of
Neurodegenerative Research3. Novel Targets for Alzheimer Pharmacotherapy:
Update on JNK3, GSK3 and Fyn kinase inhibitors and related approaches4. The
TREM2 Receptor Puzzle in Alzheimer's Disease: Assembling the Pieces5.
Phosphodiesterase: A safe and potential target for Alzheimers therapeutics6.
The NMDA receptor hypothesis in Alzheimer's disease: Unraveling the
mechanisms7. Artificial intelligence and machine learning based advances in
the management of neurodegenerative diseases8. Microglia new avenue in the
cure and treatment of Alzheimers disease9. Neuropharmacological mechanisms:
SARS CoV-210. Current perspectives on pyrazole scaffolds and their potential
impact on Alzheimer disease11. Role and therapeutic perspectives of oxidative
stress in neurodegenerative diseases12. Herbs and Natural Products for
Neurodegenerative Disorders13. Role of nanotechnology in Multiple
Sclerosis14. Therapeutic advancement in the treatment of neurodegenerative
disease15. Recent Developments in Nanotechnology Based Therapeutics for the
Treatment of Alzheimers disease. Index
Vaishali Manikaro Patil holds the position of Principal/Head at Charak School of Pharmacy, Chaudhary Charan Singh University in Meerut, India, and also serves as a Visiting Professor at the Faculty of Pharmaceutical Sciences, UCSI University in Kuala Lumpur, Malaysia. With over 17 years of academic and 3 years of industrial experience, her primary research lies in medicinal chemistry and computer-aided drug design, focusing on quantitative structureactivity relationship studies, drug-receptor interactions, and the synthesis of small heterocyclic molecules. Dr Patil, a recipient of prestigious awards, has authored numerous research papers, books, and book chapters, contributing globally through lectures and participation in scientific communities including the World Health Organization, American Chemical Society, and APTI-India.
Dileep Kumar, holding degrees from Manipal University and S.G.S.I.T.S Indore, serves as an Assistant Professor at Poona College of Pharmacy and also has a visiting faculty position at the University of California, Davis. With research interests in the design of GluN2B selective NMDA receptor antagonists and amyloid- protein aggregation inhibitors for Alzheimer's disease treatment, Dr Kumar actively contributes to cancer research at UC Davis Comprehensive Cancer Center.
Neeraj Masand, Assistant Professor at Lala Lajpat Rai Memorial Medical College in Meerut, earned degrees from North Maharashtra University and Dr. A. P. J. Abdul Kalam Technical University, Lucknow. With over 16 years of academic and research experience, his current research focuses on designing gamma-secretase inhibitors for Alzheimer's disease treatment and synthesizing novel heterocyclic analogues. Dr Masand has authored numerous research papers, books, and book chapters.
